Phase II Study of Seribantumab in Tumors Harboring NRG1 Fusions

from JCO Precision Oncology Conversations

JCO PO author Dr. Tejas Patil at University of Colorado Cancer Center shares insights into the JCO PO article, "CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions". Host Dr. Rafeh Naqash and Dr. Patil discuss the anti-tumor activity and safety data of seribantumab from the CRESTONE study (NCT04383210). LINK TO FULL TRANSCRIPT

Episode metadata supplied by the publisher feed · Published May 20, 2026

Embed this episode

Attribution link and audio player

Ready to play

Phase II Study of Seribantumab in Tumors Harboring NRG1 Fusions

0:00 22:57

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of JCO Precision Oncology Conversations?

This episode is 22 minutes long.

When was this JCO Precision Oncology Conversations episode published?

This episode was published on May 20, 2026.

Can I download this JCO Precision Oncology Conversations episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!